Neuropsychiatry

This review focuses on post-stroke depression, apathy, anxiety, and PTSD, because these disorders occur and have been studied most frequently.

Your patient is recovering from a traumatic brain injury. He asks you, “Doc, why do I need so much extra sleep?”

Here: a close up look at impulsive aggression.

What psychiatry needs is a new approach to “psychiatric theory.” Here are a few practical suggestions.

The articles mentioned here are from the Psychiatric Times Special Report on neuropsychiatry. This year, Brain Awareness Week is from March 16 to 22, 2015.

Neuropsychiatry is thriving, and the articles in this Special Report demonstrate its breadth and depth while providing the opportunity to characterize and delimit its scope.

A considerable overlap exists between TBI and disorders in cognition, behavior, and personality, which can provide even greater clinical challenges. More than 70% of the cases of TBI are mild, which makes this subgroup of particular clinical interest.

The authors take an in-depth look at the evaluation, diagnosis, and fundamental treatment recommendations, protocols, and guides to therapy for psychogenic nonepileptic seizures.

The potential of TMS as a treatment for cognitive disorders, fatigue, pain, and other manifestations of brain disease is discussed, as is the encouraging prospect for neuropsychiatric management of many patients.

Selected for clinical implications, here are some highlights from the recent acceleration in understanding of the mechanisms of bipolar disorder.

Precision medicine seems to be the new hot topic in the research world. What precisely is it?

Available data suggest that transcranial magnetic stimulation holds promise as a treatment for GAD. Here: a look at what we know.

Some recent breakthroughs, using newly developed neuroscience investigational tools, suggest that if research resources are available, we could soon make substantial advances in understanding the mechanism of action of ECT.

This is usually one of the first questions asked by patients and their families following a psychotic episode, suicide attempt, or manifestation of any serious mental illness. More from the Director of NIMH.

Can we predict risk for depression? There are no genetic tests or imaging tests that can be used to predict individual risk. But a longitudinal study at Stanford University is worth watching.

The authors review the evidence for the use of ECT and other novel neurostimulation techniques in the treatment of schizophrenia.

Although the somatizing disorders cover a vast array of symptomatic domains across many medical specialties, this article addresses the broad topic conceptually.

For severely ill patients, understanding the neurobiological underpinning of assertive coping provides an additional map for rapid assessment, formulation, and intervention to bolster assertive coping.

Although the early focus of the NIH component of the BRAIN Initiative is on tool development, the examples listed in this article show that these tools will have relevance to practicing clinicians within the lifetime of the Initiative.

An expert Q&A with Laurence Steinberg, PhD. His newest book offers insights into the malleable adolescent brain and provides guidance to parents hoping to better understand adolescents.

Advances in psychiatric research, spanning the entire spectrum of biological, psychological, and social aspects of mental processes and functions, have transformed the field of psychiatry. More in this inaugural piece by Psychiatric Times' Editor in Chief.

In his blog for Mental Illness Awareness Week, NIMH Director Thomas Insel talks about the complexity of mental disorders and the need for scientists, clinicians, patients, and families to work together in searching for better treatment.

The discovery that a single IV infusion of low-dose (subanesthetic) ketamine exerts rapid antidepressant effects constitutes an expansion in our understanding of the neurobiology of depression and provides new avenues for drug development.

We have medications that can affect serotonin, norepinephrine, and-to a lesser extent-dopamine. Many other neurotransmitters are involved with mood disorders, but we have no medications yet to target them. Neurostimulation offers a non-systemic somatic approach to depression, often with an improved side effect profile. More in this Q&A.

The SSRIs, although principally targeting serotonin transporter, are complex drugs that might work on other neurotransmitter and receptor systems. It is likely worthwhile to look at the effects of other monoamine and neuropeptide systems on the enzymatic machinery cleaving the amyloid precursor protein.